-
Is Europe and European Evidence Development an Afterthought in Pharmaceutical Early Stage Development Decisions? An Exploratory Qualitative Survey
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
Establishing Robust and Adaptive Willingness-to-Pay Thresholds for Taiwan's National Health Insurance: A Case Study of Non-Small Cell Lung Cancer
Sep 9, 2025, 16:22 PM -
Hospital Community Integration: The Case of the Territorial Oncology Center at ASL 04 Teramo
Sep 9, 2025, 16:22 PM -
Evidence-Driven Simulated Agents to Train Reinforcement Learning for Personalization in mHealth Interventions
Sep 9, 2025, 16:22 PM -
Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom
Sep 9, 2025, 16:22 PM -
Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective
Sep 9, 2025, 16:22 PM -
The HERC Database of Mapping Studies: A 2025 Update of a Live Systematic Review of Studies Predicting EQ-5D From Other Patient-Reported Outcome Measures
Sep 9, 2025, 16:22 PM -
Cognitive Debrief of the PROMIS Parent Proxy Mobility Item Bank in Caregivers of Children Living With Duchenne Muscular Dystrophy
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life in Adults With Dry Eye Disease in France: Insights From a Multicenter Observational Study
Sep 9, 2025, 16:22 PM -
Is There Sufficient Economic Evidence for Reimbursing Behavioral Interventions? A Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Linking Specialty Pharmacy Data With Healthcare Claims Data in a Rare Disease: Comprehensively Characterizing Patients With Hereditary Angioedema Treated With Berotralstat
Sep 9, 2025, 16:22 PM -
Important Risk Factors to Proxies of Treatment Failures in Patients With Major Depressive Disorder: Insights From a Claims Database Study
Sep 9, 2025, 16:22 PM -
Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Inclisiran for the Management of Patients With Atherosclerotic Cardiovascular Disease in India: A Multipayer Analysis
Sep 9, 2025, 16:22 PM -
Survival Model Uncertainty in Economic Modeling: Evaluating Bootstrap and Cholesky Decomposition Methods
Sep 9, 2025, 16:22 PM -
Applying G-methods to Account for Treatment Switching in Postmarketing Effectiveness Evaluation: A Case Study of GLP-1 Receptor Agonists for Diabetic Kidney Disease
Sep 9, 2025, 16:22 PM -
Signal Detection and Network Pharmacology Analysis of Paronychia Associated With eGFR Inhibitors
Sep 9, 2025, 16:22 PM -
Epidemiological Burden of Osteoarthritis in Eastern, Central, and Western Europe Between 1990 and 2021
Sep 9, 2025, 16:22 PM -
Mapping the Evidence on Interrelationships Between Cancer Stage Financial Toxicity (FT) and Health-Related Quality of Life (HRQoL)
Sep 9, 2025, 16:22 PM
